Senti Biosciences (NASDAQ:SNTI) & IN8bio (NASDAQ:INAB) Critical Analysis

Senti Biosciences (NASDAQ:SNTI) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Valuation & Earnings

This table compares Senti Biosciences and IN8bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$2.56 million	7.46	-$71.06 million	($15.56)	-0.25
IN8bio	N/A	N/A	-$30.01 million	($0.75)	-0.36

IN8bio has lower revenue, but higher earnings than Senti Biosciences. IN8bio is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Senti Biosciences has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Senti Biosciences and IN8bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	0	0	1	0	3.00
IN8bio	0	0	2	0	3.00

Senti Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 152.53%. IN8bio has a consensus target price of $7.75, indicating a potential upside of 2,754.51%. Given IN8bio’s higher probable upside, analysts plainly believe IN8bio is more favorable than Senti Biosciences.

Profitability

This table compares Senti Biosciences and IN8bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-154.84%	-77.42%
IN8bio	N/A	-197.15%	-130.48%

Institutional & Insider Ownership

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 10.7% of Senti Biosciences shares are owned by insiders. Comparatively, 15.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

IN8bio beats Senti Biosciences on 6 of the 11 factors compared between the two stocks.

About Senti Biosciences

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.